Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
| Image |  |
|---|---|
| Description | scientific article published on 15 May 2015 |
| Author/s |
author: Paul Lesueur Hervé Le Caer |
| Publication date | May 15, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |